Thyroid Stimulating Hormone Secreting Adenoma (TSHoma)

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pituitary thyroid stimulating hormone (TSH) hypersecreting adenomas are rarer than any other hypersecretory pituitary adenoma. The etiology of these tumors is not known. TSHomas cause central hyperthyroidism, with elevation of the thyroid hormones without suppression of TSH. Although reported to occur at most ages, there is a higher prevalence with increasing age. Most patients present with macroadenomas (>1 cm), headaches, and visual changes associated with tumor enlargement and optic nerve pathway compression. Others present with symptoms of thyrotoxicosis. Early diagnosis and treatment is recognized as the best means of avoiding complications such as vision loss, cardiac arrhythmias, or bone loss. New imaging modalities have improved diagnosis and made early treatment possible. Treatment has two goals: normalization of TSH hypersecretion and tumor control. Primary therapy is aimed at tumor removal in order to normalize TSH, but medical therapy may be indicated if hypersecretory tumor remnants remain or there is tumor regrowth. There is little data regarding long-term outcomes, late effects, or quality of life. This is likely related to the rarity of the disease.

Original languageEnglish (US)
Title of host publicationAdvanced Practice in Endocrinology Nursing
PublisherSpringer International Publishing
Pages335-342
Number of pages8
ISBN (Electronic)9783319998176
ISBN (Print)9783319998152
DOIs
StatePublished - Jan 1 2019

Keywords

  • Central hyperthyroidism
  • Pituitary adenoma
  • Thyroid stimulating hormone
  • Thyrotoxicosis
  • TSHoma

ASJC Scopus subject areas

  • Nursing(all)
  • Medicine(all)
  • Health Professions(all)

Fingerprint

Dive into the research topics of 'Thyroid Stimulating Hormone Secreting Adenoma (TSHoma)'. Together they form a unique fingerprint.

Cite this